RxDoctor Payments Data

Sandra Marcotte, DO

Family Medicine · Dyer, INNPI 1619945797

Payments from drug & device makers

$5,820in general payments, 2019–2025

Across 320 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$967
  • Novo Nordisk$799
  • Johnson & Johnson$616
  • AbbVie$582
  • Lilly USA, LLC$383
  • Pfizer$318
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$5,807100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,820 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$514,353
Medicare patients
699
Services billed
9,419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$141,587
MounjaroTirzepatide59$69,870
EliquisApixaban75$68,776
TrulicityDulaglutide36$34,807
FarxigaDapagliflozin Propanediol28$34,702
WegovySemaglutide19$30,563
JardianceEmpagliflozin21$26,829
XareltoRivaroxaban15$24,502
LinzessLinaclotide14$15,879
MyrbetriqMirabegron12$15,789
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$15,188
VeltassaPatiromer Calcium Sorbitex12$14,657
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$13,234
TradjentaLinagliptin11$12,834
ArexvyRsvpref3 Antigen/As01e/Pf36$11,251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$799$172,150121 claims
Lilly USA, LLCMounjaro, Trulicity$383$104,67695 claims
PfizerEliquis$318$68,77675 claims
AstraZenecaFarxiga, Breztri Aerosphere$147$42,94041 claims
Boehringer IngelheimJardiance, Tradjenta$32$39,66332 claims
Johnson & JohnsonXarelto$616$24,50215 claims
AbbVieLinzess, Synthroid$582$19,03965 claims
GSKArexvy, Shingrix$82$18,78470 claims
Astellas Pharma US IncMyrbetriq$179$15,78912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Dyer

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →